免疫グロブリン製品市場：タイプ、ROA、用途別-2025-2030年の世界予測

免疫グロブリン製品市場は、2023年に169億5,000万米ドルと評価され、2024年には189億2,000万米ドルに達すると予測され、CAGR 12.50％で成長し、2030年には386億7,000万米ドルに達すると予測されています。

免疫グロブリン製品は、主にヒト血漿に由来する必須生物学的製剤であり、免疫不全や自己免疫疾患の治療に使用されます。その範囲は、一次免疫不全、二次免疫不全、自己免疫疾患や炎症性疾患の管理を含む様々な治療用途を包含しています。免疫グロブリン製剤の必要性は、免疫システムを強化するという重要な役割によって強調され、免疫力が低下した患者に重要なサポートを提供しています。その用途は神経学、血液学、免疫学などの治療に及び、最終用途市場は病院、診療所、在宅医療に及んでいます。市場の洞察によると、慢性疾患の有病率の上昇、血漿分画技術の進歩、免疫グロブリン療法に対する意識の高まりが市場成長を後押しする主な要因となっています。さらに、新興国市場におけるヘルスケア支出の増加は、市場拡大の未開拓の機会をもたらしています。しかし、高額な治療費、限られた償還政策、血液媒介病原体感染のリスクなどの課題が大きな障壁となっています。生産の複雑さや規制状況の厳しさは、市場力学をさらに複雑にしています。潜在的な成長力を活用することを目指す企業にとって、技術革新は血漿の採取・分画方法の改善、遺伝子組換え免疫グロブリン製剤の開発、製剤の安定性と有効性の向上に焦点を当てるべきです。植物由来または合成生産などの代替供給源の研究開発も、有利な道筋を示す可能性があります。COVID-19パンデミックによるヘルスケア提供への影響を受けた需要パターンの変化を理解することは極めて重要です。市場は既存企業と新規参入企業が混在する中程度の競争状態にあるため、技術共有のための戦略的提携を促進し、個別化免疫グロブリン療法を重視することで、市場の差別化が図れる可能性があります。全体として、課題はあるもの、免疫グロブリン市場は、技術の進歩と効果的な治療介入を求める患者数の増加に牽引され、大きなチャンスを提供しています。

市場力学：急速に進化する免疫グロブリン製品市場の主要市場インサイトを公開

免疫グロブリン製品市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 免疫不全症患者の増加
  • 世界の老人人口の増加
  • 免疫グロブリン製剤の採用急増
• 市場抑制要因
  • 免疫グロブリン製剤の高コストと副作用
• 市場機会
  • 免疫グロブリンにおける継続的な研究開発活動
  • 免疫グロブリンの新製品と先進製品のイントロダクション
• 市場の課題
  • 製品承認のための管理団体の厳格な規則と規範

ポーターの5つの力免疫グロブリン製品市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：免疫グロブリン製品市場における外部からの影響の把握

外部マクロ環境要因は、免疫グロブリン製品市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析免疫グロブリン製品市場における競合情勢の把握

免疫グロブリン製品市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス免疫グロブリン製品市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、免疫グロブリン製品市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によりベンダーを明確かつ的確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨免疫グロブリン製品市場における成功への道筋を描く

免疫グロブリン製品市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を検討することで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 免疫不全疾患の増加
    • 世界中で増加する高齢者人口
    • 免疫グロブリン製品の採用急増
  • 抑制要因
    • 免疫グロブリン製品の高コストと副作用
  • 機会
    • 免疫グロブリンにおける進行中の研究開発活動
    • 新しく先進的な免疫グロブリン製品のイントロダクション
  • 課題
    • 製品承認に関する管理機関の厳格な規則と基準
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 免疫グロブリン製品市場：タイプ別

• 伊賀
• IGD
• ＩＧＥ
• IGG
• IGM

第7章 免疫グロブリン製品市場ROA別

• イミグ
• IVIG
• SCIG

第8章 免疫グロブリン製品市場：用途別

• CIDP
• 慢性リンパ性白血病
• 先天性エイズ
• 低ガンマグロブリン血症
• 免疫不全疾患
• 免疫グロブリン
• 川崎病
• 多巣性運動神経障害
• 重症筋無力症

第9章 南北アメリカの免疫グロブリン製品市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の免疫グロブリン製品市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの免疫グロブリン製品市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• ADMA Biologics, Inc.
• Baxter International Inc.
• Bayer AG
• Beckman Coulter, Inc.
• Bio Products Laboratory Ltd.
• Biotest AG
• China Biologic Products Holdings, Inc.
• CSL Limited
• Emergent BioSolutions Inc.
• Evolve Biologics Inc.
• F. Hoffmann-La Roche AG
• GigaGen, Inc.
• Grifols, S.A.
• Horizon Therapeutics PLC
• ImmunOs Therapeutics AG
• Kamada Ltd.
• Kedrion S.p.A
• Leadiant Biosciences, Inc.
• LFB S.A
• Octapharma AG
• Pfizer Inc.
• Sanquin Plasma Products B.V.
• Takeda Pharmaceutical Company Limited

LIST OF FIGURES

• FIGURE 1. IMMUNOGLOBULIN PRODUCT MARKET RESEARCH PROCESS
• FIGURE 2. IMMUNOGLOBULIN PRODUCT MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROA, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROA, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. IMMUNOGLOBULIN PRODUCT MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. IMMUNOGLOBULIN PRODUCT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. IMMUNOGLOBULIN PRODUCT MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. IMMUNOGLOBULIN PRODUCT MARKET DYNAMICS
• TABLE 7. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY IGA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY IGD, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY IGE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY IGG, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY IGM, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROA, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY IMIG, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY IVIG, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY SCIG, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY CIDP, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY CLL, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY CONGENITAL AIDS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY HYPOGAMMAGLOBULINEMIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY IMMUNODEFICIENCY DISEASES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ITP, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY KAWASAKI DISEASE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY MULTIFOCAL MOTOR NEUROPATHY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY MYASTHENIA GRAVIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. AMERICAS IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROA, 2018-2030 (USD MILLION)
• TABLE 29. AMERICAS IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 30. AMERICAS IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 31. ARGENTINA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 32. ARGENTINA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROA, 2018-2030 (USD MILLION)
• TABLE 33. ARGENTINA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 34. BRAZIL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 35. BRAZIL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROA, 2018-2030 (USD MILLION)
• TABLE 36. BRAZIL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 37. CANADA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 38. CANADA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROA, 2018-2030 (USD MILLION)
• TABLE 39. CANADA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 40. MEXICO IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 41. MEXICO IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROA, 2018-2030 (USD MILLION)
• TABLE 42. MEXICO IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 43. UNITED STATES IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 44. UNITED STATES IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROA, 2018-2030 (USD MILLION)
• TABLE 45. UNITED STATES IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 46. UNITED STATES IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 47. ASIA-PACIFIC IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 48. ASIA-PACIFIC IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROA, 2018-2030 (USD MILLION)
• TABLE 49. ASIA-PACIFIC IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 50. ASIA-PACIFIC IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 51. AUSTRALIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 52. AUSTRALIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROA, 2018-2030 (USD MILLION)
• TABLE 53. AUSTRALIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 54. CHINA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 55. CHINA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROA, 2018-2030 (USD MILLION)
• TABLE 56. CHINA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 57. INDIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 58. INDIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROA, 2018-2030 (USD MILLION)
• TABLE 59. INDIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 60. INDONESIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 61. INDONESIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROA, 2018-2030 (USD MILLION)
• TABLE 62. INDONESIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 63. JAPAN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 64. JAPAN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROA, 2018-2030 (USD MILLION)
• TABLE 65. JAPAN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 66. MALAYSIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 67. MALAYSIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROA, 2018-2030 (USD MILLION)
• TABLE 68. MALAYSIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 69. PHILIPPINES IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 70. PHILIPPINES IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROA, 2018-2030 (USD MILLION)
• TABLE 71. PHILIPPINES IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 72. SINGAPORE IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 73. SINGAPORE IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROA, 2018-2030 (USD MILLION)
• TABLE 74. SINGAPORE IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 75. SOUTH KOREA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 76. SOUTH KOREA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROA, 2018-2030 (USD MILLION)
• TABLE 77. SOUTH KOREA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 78. TAIWAN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 79. TAIWAN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROA, 2018-2030 (USD MILLION)
• TABLE 80. TAIWAN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 81. THAILAND IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 82. THAILAND IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROA, 2018-2030 (USD MILLION)
• TABLE 83. THAILAND IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 84. VIETNAM IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 85. VIETNAM IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROA, 2018-2030 (USD MILLION)
• TABLE 86. VIETNAM IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 87. EUROPE, MIDDLE EAST & AFRICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 88. EUROPE, MIDDLE EAST & AFRICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROA, 2018-2030 (USD MILLION)
• TABLE 89. EUROPE, MIDDLE EAST & AFRICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 90. EUROPE, MIDDLE EAST & AFRICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 91. DENMARK IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 92. DENMARK IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROA, 2018-2030 (USD MILLION)
• TABLE 93. DENMARK IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 94. EGYPT IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 95. EGYPT IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROA, 2018-2030 (USD MILLION)
• TABLE 96. EGYPT IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 97. FINLAND IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 98. FINLAND IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROA, 2018-2030 (USD MILLION)
• TABLE 99. FINLAND IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 100. FRANCE IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 101. FRANCE IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROA, 2018-2030 (USD MILLION)
• TABLE 102. FRANCE IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 103. GERMANY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 104. GERMANY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROA, 2018-2030 (USD MILLION)
• TABLE 105. GERMANY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 106. ISRAEL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 107. ISRAEL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROA, 2018-2030 (USD MILLION)
• TABLE 108. ISRAEL IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 109. ITALY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 110. ITALY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROA, 2018-2030 (USD MILLION)
• TABLE 111. ITALY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 112. NETHERLANDS IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 113. NETHERLANDS IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROA, 2018-2030 (USD MILLION)
• TABLE 114. NETHERLANDS IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 115. NIGERIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 116. NIGERIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROA, 2018-2030 (USD MILLION)
• TABLE 117. NIGERIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 118. NORWAY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 119. NORWAY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROA, 2018-2030 (USD MILLION)
• TABLE 120. NORWAY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 121. POLAND IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 122. POLAND IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROA, 2018-2030 (USD MILLION)
• TABLE 123. POLAND IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 124. QATAR IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 125. QATAR IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROA, 2018-2030 (USD MILLION)
• TABLE 126. QATAR IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 127. RUSSIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 128. RUSSIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROA, 2018-2030 (USD MILLION)
• TABLE 129. RUSSIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 130. SAUDI ARABIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 131. SAUDI ARABIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROA, 2018-2030 (USD MILLION)
• TABLE 132. SAUDI ARABIA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 133. SOUTH AFRICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 134. SOUTH AFRICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROA, 2018-2030 (USD MILLION)
• TABLE 135. SOUTH AFRICA IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 136. SPAIN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 137. SPAIN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROA, 2018-2030 (USD MILLION)
• TABLE 138. SPAIN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 139. SWEDEN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 140. SWEDEN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROA, 2018-2030 (USD MILLION)
• TABLE 141. SWEDEN IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 142. SWITZERLAND IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 143. SWITZERLAND IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROA, 2018-2030 (USD MILLION)
• TABLE 144. SWITZERLAND IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 145. TURKEY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 146. TURKEY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROA, 2018-2030 (USD MILLION)
• TABLE 147. TURKEY IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 148. UNITED ARAB EMIRATES IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 149. UNITED ARAB EMIRATES IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROA, 2018-2030 (USD MILLION)
• TABLE 150. UNITED ARAB EMIRATES IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 151. UNITED KINGDOM IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 152. UNITED KINGDOM IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY ROA, 2018-2030 (USD MILLION)
• TABLE 153. UNITED KINGDOM IMMUNOGLOBULIN PRODUCT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
• TABLE 154. IMMUNOGLOBULIN PRODUCT MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 155. IMMUNOGLOBULIN PRODUCT MARKET, FPNV POSITIONING MATRIX, 2023

The Immunoglobulin Product Market was valued at USD 16.95 billion in 2023, expected to reach USD 18.92 billion in 2024, and is projected to grow at a CAGR of 12.50%, to USD 38.67 billion by 2030.

Immunoglobulin products are essential biological products derived primarily from human plasma, used to treat immune deficiencies and autoimmune disorders. Their scope encompasses various therapeutic applications, including management of primary immune deficiencies, secondary immune deficiencies, and autoimmune and inflammatory diseases. The necessity of immunoglobulin products is underscored by their crucial role in bolstering the immune system, offering vital support to patients with compromised immunity. Their applications extend to treatments in neurology, hematology, and immunology, with end-use markets spanning hospitals, clinics, and homecare settings. Market insights reveal that the rising prevalence of chronic diseases, advancements in plasma fractionation technologies, and growing awareness surrounding immunoglobulin therapies are key factors boosting market growth. Additionally, increased healthcare expenditure in developing regions presents untapped opportunities for market expansion. However, challenges such as the high cost of treatment, limited reimbursement policies, and the risk of blood-borne pathogen transmission pose significant barriers. The complexity of production and stringent regulatory landscapes further complicate market dynamics. For businesses aiming to capitalize on potential growth, innovation should focus on improving plasma collection and fractionation methods, developing recombinant immunoglobulin products, and enhancing formulation stability and efficacy. R&D into alternative sources, such as plant-based or synthetic production, may also present lucrative pathways. Understanding the demand pattern shifts, driven by the COVID-19 pandemic's impact on healthcare delivery, is crucial. As the market is moderately competitive with a mix of established players and new entrants, fostering strategic alliances for technology sharing and emphasizing personalized immunoglobulin therapies could provide market differentiation. Overall, despite its challenges, the immunoglobulin market offers significant opportunities, driven by technological advancements and a growing patient population demanding effective therapeutic interventions.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Immunoglobulin Product Market

The Immunoglobulin Product Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rise in the Cases of Immunodeficiency Diseases
  • Growing Geriatric Population Around the World
  • Surge in the Adoption of Immunoglobulin Products
• Market Restraints
  • High Cost and Adverse Effects of the Immunoglobulin Products
• Market Opportunities
  • Ongoing Research and Development Activities in the Immunoglobulin
  • Introduction of New & Advanced Immunoglobulin Products
• Market Challenges
  • Strict Rules and Norms of Governing Bodies for Product Approval

Porter's Five Forces: A Strategic Tool for Navigating the Immunoglobulin Product Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Immunoglobulin Product Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Immunoglobulin Product Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Immunoglobulin Product Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Immunoglobulin Product Market

A detailed market share analysis in the Immunoglobulin Product Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Immunoglobulin Product Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Immunoglobulin Product Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Immunoglobulin Product Market

A strategic analysis of the Immunoglobulin Product Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Immunoglobulin Product Market, highlighting leading vendors and their innovative profiles. These include ADMA Biologics, Inc., Baxter International Inc., Bayer AG, Beckman Coulter, Inc., Bio Products Laboratory Ltd., Biotest AG, China Biologic Products Holdings, Inc., CSL Limited, Emergent BioSolutions Inc., Evolve Biologics Inc., F. Hoffmann-La Roche AG, GigaGen, Inc., Grifols, S.A., Horizon Therapeutics PLC, ImmunOs Therapeutics AG, Kamada Ltd., Kedrion S.p.A, Leadiant Biosciences, Inc., LFB S.A, Octapharma AG, Pfizer Inc., Sanquin Plasma Products B.V., and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage

This research report categorizes the Immunoglobulin Product Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across IGA, IGD, IGE, IGG, and IGM.
• Based on ROA, market is studied across IMIG, IVIG, and SCIG.
• Based on Application, market is studied across CIDP, CLL, Congenital AIDS, Hypogammaglobulinemia, Immunodeficiency Diseases, ITP, Kawasaki Disease, Multifocal Motor Neuropathy, and Myasthenia Gravis.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rise in the Cases of Immunodeficiency Diseases
    • 5.1.1.2. Growing Geriatric Population Around the World
    • 5.1.1.3. Surge in the Adoption of Immunoglobulin Products
  • 5.1.2. Restraints
    • 5.1.2.1. High Cost and Adverse Effects of the Immunoglobulin Products
  • 5.1.3. Opportunities
    • 5.1.3.1. Ongoing Research and Development Activities in the Immunoglobulin
    • 5.1.3.2. Introduction of New & Advanced Immunoglobulin Products
  • 5.1.4. Challenges
    • 5.1.4.1. Strict Rules and Norms of Governing Bodies for Product Approval
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Immunoglobulin Product Market, by Type

• 6.1. Introduction
• 6.2. IGA
• 6.3. IGD
• 6.4. IGE
• 6.5. IGG
• 6.6. IGM

7. Immunoglobulin Product Market, by ROA

• 7.1. Introduction
• 7.2. IMIG
• 7.3. IVIG
• 7.4. SCIG

8. Immunoglobulin Product Market, by Application

• 8.1. Introduction
• 8.2. CIDP
• 8.3. CLL
• 8.4. Congenital AIDS
• 8.5. Hypogammaglobulinemia
• 8.6. Immunodeficiency Diseases
• 8.7. ITP
• 8.8. Kawasaki Disease
• 8.9. Multifocal Motor Neuropathy
• 8.10. Myasthenia Gravis

9. Americas Immunoglobulin Product Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Immunoglobulin Product Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Immunoglobulin Product Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. ADMA Biologics, Inc.
• 2. Baxter International Inc.
• 3. Bayer AG
• 4. Beckman Coulter, Inc.
• 5. Bio Products Laboratory Ltd.
• 6. Biotest AG
• 7. China Biologic Products Holdings, Inc.
• 8. CSL Limited
• 9. Emergent BioSolutions Inc.
• 10. Evolve Biologics Inc.
• 11. F. Hoffmann-La Roche AG
• 12. GigaGen, Inc.
• 13. Grifols, S.A.
• 14. Horizon Therapeutics PLC
• 15. ImmunOs Therapeutics AG
• 16. Kamada Ltd.
• 17. Kedrion S.p.A
• 18. Leadiant Biosciences, Inc.
• 19. LFB S.A
• 20. Octapharma AG
• 21. Pfizer Inc.
• 22. Sanquin Plasma Products B.V.
• 23. Takeda Pharmaceutical Company Limited